Related Experiment Video

Updated: Oct 4, 2025

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
06:17

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

706

Deciphering the Mechanism of Binding Selectivity of Chlorofluoroacetamide-Based Covalent Inhibitors toward

Farideh Badichi Akher1,2,3, Abdolkarim Farrokhzadeh2, Neil Ravenscroft2

  • 1Department of Computer Science, University of Cape Town, Cape Town 7700, South Africa.

Journal of Chemical Information and Modeling
|February 4, 2022
PubMed

Insights

NSP-037, a novel irreversible inhibitor, shows superior selectivity for the double-mutant epidermal growth factor receptor (EGFR) in non-small-cell lung cancer treatment compared to osimertinib. Computational studies reveal its unique binding mechanism enhances selectivity.

Area of Science:

  • Oncology
  • Pharmacology
  • Computational Chemistry

Background:

  • Covalent modification of oncogenic mutant epidermal growth factor receptor (EGFR) is key for non-small-cell lung cancer treatment.
  • NSP-037 (18) is an irreversible inhibitor targeting L858R/T790M double-mutant EGFR (EGFRDM).
  • NSP-037 exhibits seven-fold greater selectivity for EGFRDM over wild-type EGFR (EGFRWT) than osimertinib (7).

Purpose of the Study:

  • To elucidate the mechanism behind NSP-037's enhanced selectivity using computational approaches.
  • To understand the role of the novel α-chlorofluoroacetamide (CFA) warhead in selectivity enhancement.
  • To compare the binding mechanisms of NSP-037 and osimertinib.

Main Methods:

  • Multiple computational approaches were employed.
  • Analysis of conformational changes upon inhibitor binding.
  • Binding free energy calculations and free energy decomposition.
  • Quantum mechanics/molecular mechanics (QM/MM) calculations for reaction mechanism.

Main Results:

  • EGFRDM exhibits significantly larger conformational changes than EGFRWT upon binding to NSP-037.
  • Conformational stability of NSP-037's diamine side chain and CFA motif is crucial for its selective binding.
  • NSP-037 demonstrates a binding free energy 6.38 kcal/mol greater than osimertinib.
  • Electrostatic contributions from key residues significantly influence binding.
  • Direct displacement via the CFA warhead is the favored mechanism for Cys797 alkylation.

Conclusions:

  • NSP-037's unique binding mechanism and CFA warhead confer superior selectivity for EGFRDM.
  • Computational methods successfully elucidated the molecular basis of enhanced selectivity.
  • NSP-037 represents a promising therapeutic strategy for non-small-cell lung cancer with specific EGFR mutations.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.5K
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

2.7K

Related Concept Videos

Drug-Receptor Bonds01:25

Drug-Receptor Bonds

Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
3.6K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.0K
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
13.9K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.1K